Allergan expands Refresh eye treatment portfolio
A trifecta of relief formulated with HydroCell technology offers new artificial tear options for patients suffering from eye dryness.
Allergan has launched three new over-the-counter (OTC) Refresh Relieva products: Refresh Relieva; Refresh Relieva PF (preservative-free) multidose; and Refresh Relieva for Contacts.
This new line of artificial tear formulations available in preserved, preservative-free multidose, and a formula designed for contact lens wearers, are specially formulated to relieve discomfort due to eye dryness and to prevent further irritation. Refresh, a doctor recommended brand of artificial tears, continues to expand its portfolio by offering the only family of products in the US with carboxymethylcellulose (CMC), hyaluronic acid (HA, an inactive ingredient), glycerin, and HydroCell technology - Allergan's proprietary sodium chloride (NaCl) free, glycerin-based solution that enables hydration and maintains the volume of cells on the ocular surface.
"We are pleased to expand our robust artificial tear portfolio with Refresh Relieva products as we continue to exemplify our commitment to innovation in eye care. This brand-new line provides doctors and patients with three unique options to treat patients' individual needs when it comes to dry, irritated eyes and contact lens dryness," said Jag Dosanjh, Senior Vice President, Allergan US Eye Care. "With Refresh Relieva for Contacts, contact lens patients now have a new option. As the number one selling brand in preservative-free artificial tears, it was also important to us to introduce Refresh Relieva in a new, convenient preservative-free bottle. Now patients can enjoy the convenience of a multidose bottle with all the benefits of being preservative-free."
Over 26 million people in the US suffer from symptoms of eye dryness, including irritation, burning, dryness, and discomfort. Eye dryness can be caused by advanced age, contact lens wear, certain medications, other medical conditions, or environmental factors. Studies show Refresh Relieva products improve the symptoms of eye dryness in patients, with a low incidence of blur upon installation.
70% of patients reported no blur when Refresh Relieva and Refresh Relieva for Contacts was first applied.
"As eye dryness varies for each patient, I'm excited to have three new artificial tear treatment options since we know that one size doesn't fit all for patients," said Milton Hom, OD. "Different patients have different needs and Refresh Relieva provides the diversity to satisfy more patients. With a low-blur formula and HydroCell technology Refresh Relieva will be my preferred artificial tear."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.